The Experts below are selected from a list of 6822 Experts worldwide ranked by ideXlab platform
Poonkiat Suchonwanit - One of the best experts on this subject based on the ideXlab platform.
-
Minoxidil and its use in hair disorders a review
Drug Design Development and Therapy, 2019Co-Authors: Poonkiat Suchonwanit, Sasima Thammarucha, Kanchana LeerunyakulAbstract:Minoxidil was first introduced as an antihypertensive medication and the discovery of its common adverse event, hypertrichosis, led to the development of a topical formulation for promoting hair growth. To date, topical Minoxidil is the mainstay treatment for androgenetic alopecia and is used as an off-label treatment for other hair loss conditions. Despite its widespread application, the exact mechanism of action of Minoxidil is still not fully understood. In this article, we aim to review and update current information on the pharmacology, mechanism of action, clinical efficacy, and adverse events of topical Minoxidil.
-
Efficacy of Topical Combination of 0.25% Finasteride and 3% Minoxidil Versus 3% Minoxidil Solution in Female Pattern Hair Loss: A Randomized, Double-Blind, Controlled Study
American Journal of Clinical Dermatology, 2019Co-Authors: Poonkiat Suchonwanit, Wimolsiri Iamsumang, Salinee RojhirunsakoolAbstract:Background The relationship between female pattern hair loss (FPHL) and androgenic hormones is not well established, but some evidence indicates oral finasteride may be efficacious in FPHL. Use of a topical formulation has been proposed to minimize unwanted effects. Objectives Our objective was to compare the efficacy and safety of topical 0.25% finasteride combined with 3% Minoxidil solution and 3% Minoxidil solution as monotherapy in the treatment of FPHL. Methods This was a prospective, randomized, double-blind study in 30 postmenopausal women with FPHL. Each participant was randomized to receive either topical 0.25% finasteride combined with topical 3% Minoxidil or topical 3% Minoxidil solution as monotherapy for 24 weeks. To determine efficacy, the hair density and diameter was measured and global photographic assessment was conducted at baseline and 8, 16, and 24 weeks. Side effects and serum dihydrotestosterone levels were also evaluated. Results By 24 weeks, hair density and diameter had increased in both groups, and finasteride/Minoxidil was significantly superior to Minoxidil solution in terms of hair diameter ( p = 0.039). No systemic side effects were reported. However, serum dihydrotestosterone levels in the finasteride/Minoxidil group significantly decreased from baseline ( p = 0.016). Conclusion A topical combination of 0.25% finasteride and 3% Minoxidil may be a promising option in the treatment of FPHL with an additional benefit of increasing hair diameter. Nevertheless, as it may be absorbed percutaneously, it should be reserved for postmenopausal women. Trial Registration clinicaltrials.in.th; identifier TCTR20160912002.
-
efficacy of topical combination of 0 25 finasteride and 3 Minoxidil versus 3 Minoxidil solution in female pattern hair loss a randomized double blind controlled study
American Journal of Clinical Dermatology, 2019Co-Authors: Poonkiat Suchonwanit, Wimolsiri Iamsumang, Salinee RojhirunsakoolAbstract:Background The relationship between female pattern hair loss (FPHL) and androgenic hormones is not well established, but some evidence indicates oral finasteride may be efficacious in FPHL. Use of a topical formulation has been proposed to minimize unwanted effects. Objectives Our objective was to compare the efficacy and safety of topical 0.25% finasteride combined with 3% Minoxidil solution and 3% Minoxidil solution as monotherapy in the treatment of FPHL. Methods This was a prospective, randomized, double-blind study in 30 postmenopausal women with FPHL. Each participant was randomized to receive either topical 0.25% finasteride combined with topical 3% Minoxidil or topical 3% Minoxidil solution as monotherapy for 24 weeks. To determine efficacy, the hair density and diameter was measured and global photographic assessment was conducted at baseline and 8, 16, and 24 weeks. Side effects and serum dihydrotestosterone levels were also evaluated. Results By 24 weeks, hair density and diameter had increased in both groups, and finasteride/Minoxidil was significantly superior to Minoxidil solution in terms of hair diameter (p = 0.039). No systemic side effects were reported. However, serum dihydrotestosterone levels in the finasteride/Minoxidil group significantly decreased from baseline (p = 0.016). Conclusion A topical combination of 0.25% finasteride and 3% Minoxidil may be a promising option in the treatment of FPHL with an additional benefit of increasing hair diameter. Nevertheless, as it may be absorbed percutaneously, it should be reserved for postmenopausal women. Trial registration clinicaltrials.in.th; identifier TCTR20160912002.
-
a randomized double blind controlled study of the efficacy and safety of topical solution of 0 25 finasteride admixed with 3 Minoxidil vs 3 Minoxidil solution in the treatment of male androgenetic alopecia
Journal of The European Academy of Dermatology and Venereology, 2018Co-Authors: Poonkiat Suchonwanit, Ploychompoo Srisuwanwattana, N Chalermroj, Saranya KhunkhetAbstract:BACKGROUND The synergism of combined use between oral finasteride and topical Minoxidil has been established in treating androgenetic alopecia among men. However, the concern regarding adverse effects of finasteride use has been rising. OBJECTIVE To compare the efficacy and safety of topical solution of 0.25% finasteride admixed with 3% Minoxidil vs. 3% Minoxidil solution in men with androgenetic alopecia. METHODS Forty men aged 18-60 years with androgenetic alopecia were randomized to 24 weeks of treatment with a finasteride/Minoxidil or Minoxidil solution twice daily. Primary efficacy endpoint was the change from baseline in hair density and hair diameter at week 24. Secondary endpoints included global photographic assessment by treatment-blinded investigators and subjects. Changes in plasma dihydrotestosterone levels and adverse events were recorded. RESULTS At week 24, the combined solution of finasteride and Minoxidil was significantly superior to Minoxidil alone in improvements of hair density, hair diameter and global photographic assessment (all P < 0.05). About 90% of patients treated with the combined solution experienced moderate to marked improvement. The combined solution also had minimal effect on plasma dihydrotestosterone levels, approximately 5% reduction. There were also no systemic adverse events reported by patients in both groups. CONCLUSION Treatment with topical solution of 0.25% finasteride admixed with 3% Minoxidil was significantly superior to 3% Minoxidil solution for promoting hair growth in male androgenetic alopecia, and well tolerated.
Andy Goren - One of the best experts on this subject based on the ideXlab platform.
-
Novel "After Minoxidil" spray improves topical Minoxidil compliance and hair style manageability.
Journal of cosmetic dermatology, 2020Co-Authors: Maja Kovacevic, John Mccoy, Jerry Shapiro, Rodney Sinclair, Sergio Vano-galvan, Mohamad Goldust, Mirna Šitum, Andy GorenAbstract:BACKGROUND Topical Minoxidil is the only US FDA-approved drug for the treatment of female pattern hair loss (FPHL). While the safety profile of topical Minoxidil is excellent, the efficacy of Minoxidil in hair growth is extremely low. A recent survey of 8000 people observed that only 4% of hair loss patients using an over-the-counter Minoxidil were very satisfied with their results. In contrast, in clinical studies with an intervening physician, approximately 30%-40% of patients demonstrate an appreciable benefit. Compliance with topical drug regimens is often a major obstacle, limiting their effectiveness. Topical Minoxidil leaves a greasy residue on the hair, which is especially problematic for women who do not wash their hair daily. AIMS We set out to develop an "After Minoxidil" companion spray to Minoxidil that removes residual Minoxidil from the hair, where it is not needed, yet leaves Minoxidil on the scalp where it is required. We hypothesized that improving the cosmetic properties of Minoxidil would improve patient compliance with the drug and subsequently improve clinical outcomes. METHODS A cohort of 20 FPHL patients was recruited to use the novel "After Minoxidil" spray and report changes in hair quality on a Likert scale. RESULTS In our cohort of FPHL patients, the novel "After Minoxidil" spray restored ease of styling and reduced greasiness to preMinoxidil level in 65% and 85% of subjects, respectively. The average reduction in perceived greasiness was 78%. Importantly, 70% of subjects interviewed stated they would likely continue to use the Minoxidil and "After Minoxidil" treatment regimen for 6 months, vs 0% willing to use Minoxidil alone. CONCLUSION The novel "After Minoxidil" spray improved ease of hair styling and reduced greasiness following application of topical Minoxidil; thus, the novel "After Minoxidil" spray may help improve drug compliance and efficacy.
-
low dose daily aspirin reduces topical Minoxidil efficacy in androgenetic alopecia patients
Dermatologic Therapy, 2018Co-Authors: Andy Goren, Maja Kovacevic, Jerry Shapiro, Rodney Sinclair, Mohamad Goldust, Mirna Šitum, Aseem Sharma, Rachita Dhurat, Lukinovic V Skudar, Torello LottiAbstract:Topical Minoxidil is the only US FDA approved OTC drug for the treatment of androgenetic alopecia (AGA). Minoxidil is a pro-drug converted into its active form, Minoxidil sulfate, by the sulfotransferase enzymes in the outer root sheath of hair follicles. Previously, we demonstrated that sulfotransferase activity in hair follicles predicts response to topical Minoxidil in the treatment of AGA. In the human liver, sulfotransferase activity is significantly inhibited by salicylic acid. Low-dose OTC aspirin (75-81 mg), a derivative of salicylic acid, is used by millions of people daily for the prevention of coronary heart disease and cancer. It is not known whether oral aspirin inhibits sulfotransferase activity in hair follicles, potentially affecting Minoxidil response in AGA patients. In the present study, we determined the follicular sulfotransferase enzymatic activity following 14 days of oral aspirin administration. In our cohort of 24 subjects, 50% were initially predicted to be responders to Minoxidil. However, following 14 days of aspirin administration, only 27% of the subjects were predicted to respond to topical Minoxidil. To the best of our knowledge, this is the first study to report the effect of low-dose daily aspirin use on the efficacy of topical Minoxidil.
-
the effect of topical Minoxidil treatment on follicular sulfotransferase enzymatic activity
Journal of Biological Regulators and Homeostatic Agents, 2018Co-Authors: Andy Goren, Maja Kovacevic, John Mccoy, Mirna Šitum, Rachita Dhurat, J Chitalia, T Naccarato, Torello LottiAbstract:Minoxidil is the only US FDA-approved topical drug for the treatment of female and male pattern hair loss. Previously, it was demonstrated that topical Minoxidil is metabolized to its active metabolite, Minoxidil sulfate, by sulfotransferase enzymes located in the outer root sheath of hair follicles. The expression of sulfotransferase in the scalp varies greatly between individuals, and this difference in expression explains the varied response to Minoxidil treatment. Previously, we have demonstrated the clinical utility of detecting sulfotransferase in plucked hair follicles to predict Minoxidil response in pattern hair loss patients. Typically, exogenous exposure to substrates affects the expression of the enzymatic system responsible for their metabolism. For example, Phase I metabolizing enzymes, such as the cytochrome P450 family of enzymes, are known to be up-regulated in the presence of xenobiotic substrates. However, it is not known if Phase II metabolizing enzymes, such as the sulfotransferase family of enzymes, are similarly affected by the presence of substrates. In this study, we recruited 120 subjects and analyzed their sulfotransferase enzymatic activity before and after treatment with topical Minoxidil. Adjusting the results for biologic (within subject) variability, we discovered that the sulfotransferase enzymatic system expression is stable over the course of Minoxidil treatment. To the best of our knowledge, this is the first study to demonstrate the stability of sulfotransferase, a Phase II metabolizing enzyme, over the course of Minoxidil treatment.
-
Minoxidil dose response study in female pattern hair loss patients determined to be non-responders to 5% topical Minoxidil.
Journal of biological regulators and homeostatic agents, 2016Co-Authors: John Mccoy, Maja Kovacevic, Andy Goren, Jerry ShapiroAbstract:Topical Minoxidil is the only US FDA approved drug for the treatment of female pattern hair loss (FPHL). 5% Minoxidil foam is only effective at re-growing hair in a minority of women (approximately 40%). Thus, the majority of FPHL patients remain untreated. Previously, we demonstrated that nonresponders to 5% Minoxidil have low metabolism of Minoxidil in hair follicles. As such, we hypothesized that increasing the dosage of topical Minoxidil to low metabolizers would increase the number of responders without increasing the incidence of adverse events. In this study, we recruited FPHL subjects that were identified as non-responders to 5% topical Minoxidil utilizing the previously validated assay for Minoxidil response. Subjects were treated for 12 weeks with a novel 15% topical Minoxidil solution. At 12 weeks, 60% of subjects achieved a clinically significant response based on target area hair counts (>13.7% from baseline), as well as significant improvement in global photographic assessment. None of the subjects experienced significant hemodynamic changes or any other adverse events. To the best of our knowledge, this is the first study to demonstrate the potentially beneficial effect of a higher dosage of Minoxidil in FPHL subjects who fail to respond to 5% Minoxidil.
-
doppler laser imaging predicts response to topical Minoxidil in the treatment of female pattern hair loss
Journal of Biological Regulators and Homeostatic Agents, 2016Co-Authors: John Mccoy, Maja Kovacevic, Mirna Šitum, Andrija Stanimirovic, Zeljana Bolanca, Andy GorenAbstract:Topical Minoxidil is the only drug approved by the US FDA for the treatment of female pattern hair loss. Unfortunately, following 16 weeks of daily application, less than 40% of patients regrow hair. Several studies have demonstrated that sulfotransferase enzyme activity in plucked hair follicles predicts topical Minoxidil response in female pattern hair loss patients. However, due to patients discomfort with the procedure, and the time required to perform the enzymatic assay it would be ideal to develop a rapid, non-invasive test for sulfotransferase enzyme activity. Minoxidil is a pro-drug converted to its active form, Minoxidil sulfate, by sulfotransferase enzymes in the outer root sheath of hair. Minoxidil sulfate is the active form required for both the promotion of hair regrowth and the vasodilatory effects of Minoxidil. We thus hypothesized that laser Doppler velocimetry measurement of scalp blood perfusion subsequent to the application of topical Minoxidil would correlate with sulfotransferase enzyme activity in plucked hair follicles. In this study, plucked hair follicles from female pattern hair loss patients were analyzed for sulfotransferase enzyme activity. Additionally, laser Doppler velocimetry was used to measure the change in scalp perfusion at 15, 30, 45, and 60 minutes, after the application of Minoxidil. In agreement with our hypothesis, we discovered a correlation (r=1.0) between the change in scalp perfusion within 60 minutes after topical Minoxidil application and sulfotransferase enzyme activity in plucked hairs. To our knowledge, this is the first study demonstrating the feasibility of using laser Doppler imaging as a rapid, non-invasive diagnostic test to predict topical Minoxidil response in the treatment of female pattern hair loss.
Salinee Rojhirunsakool - One of the best experts on this subject based on the ideXlab platform.
-
Efficacy of Topical Combination of 0.25% Finasteride and 3% Minoxidil Versus 3% Minoxidil Solution in Female Pattern Hair Loss: A Randomized, Double-Blind, Controlled Study
American Journal of Clinical Dermatology, 2019Co-Authors: Poonkiat Suchonwanit, Wimolsiri Iamsumang, Salinee RojhirunsakoolAbstract:Background The relationship between female pattern hair loss (FPHL) and androgenic hormones is not well established, but some evidence indicates oral finasteride may be efficacious in FPHL. Use of a topical formulation has been proposed to minimize unwanted effects. Objectives Our objective was to compare the efficacy and safety of topical 0.25% finasteride combined with 3% Minoxidil solution and 3% Minoxidil solution as monotherapy in the treatment of FPHL. Methods This was a prospective, randomized, double-blind study in 30 postmenopausal women with FPHL. Each participant was randomized to receive either topical 0.25% finasteride combined with topical 3% Minoxidil or topical 3% Minoxidil solution as monotherapy for 24 weeks. To determine efficacy, the hair density and diameter was measured and global photographic assessment was conducted at baseline and 8, 16, and 24 weeks. Side effects and serum dihydrotestosterone levels were also evaluated. Results By 24 weeks, hair density and diameter had increased in both groups, and finasteride/Minoxidil was significantly superior to Minoxidil solution in terms of hair diameter ( p = 0.039). No systemic side effects were reported. However, serum dihydrotestosterone levels in the finasteride/Minoxidil group significantly decreased from baseline ( p = 0.016). Conclusion A topical combination of 0.25% finasteride and 3% Minoxidil may be a promising option in the treatment of FPHL with an additional benefit of increasing hair diameter. Nevertheless, as it may be absorbed percutaneously, it should be reserved for postmenopausal women. Trial Registration clinicaltrials.in.th; identifier TCTR20160912002.
-
efficacy of topical combination of 0 25 finasteride and 3 Minoxidil versus 3 Minoxidil solution in female pattern hair loss a randomized double blind controlled study
American Journal of Clinical Dermatology, 2019Co-Authors: Poonkiat Suchonwanit, Wimolsiri Iamsumang, Salinee RojhirunsakoolAbstract:Background The relationship between female pattern hair loss (FPHL) and androgenic hormones is not well established, but some evidence indicates oral finasteride may be efficacious in FPHL. Use of a topical formulation has been proposed to minimize unwanted effects. Objectives Our objective was to compare the efficacy and safety of topical 0.25% finasteride combined with 3% Minoxidil solution and 3% Minoxidil solution as monotherapy in the treatment of FPHL. Methods This was a prospective, randomized, double-blind study in 30 postmenopausal women with FPHL. Each participant was randomized to receive either topical 0.25% finasteride combined with topical 3% Minoxidil or topical 3% Minoxidil solution as monotherapy for 24 weeks. To determine efficacy, the hair density and diameter was measured and global photographic assessment was conducted at baseline and 8, 16, and 24 weeks. Side effects and serum dihydrotestosterone levels were also evaluated. Results By 24 weeks, hair density and diameter had increased in both groups, and finasteride/Minoxidil was significantly superior to Minoxidil solution in terms of hair diameter (p = 0.039). No systemic side effects were reported. However, serum dihydrotestosterone levels in the finasteride/Minoxidil group significantly decreased from baseline (p = 0.016). Conclusion A topical combination of 0.25% finasteride and 3% Minoxidil may be a promising option in the treatment of FPHL with an additional benefit of increasing hair diameter. Nevertheless, as it may be absorbed percutaneously, it should be reserved for postmenopausal women. Trial registration clinicaltrials.in.th; identifier TCTR20160912002.
John Mccoy - One of the best experts on this subject based on the ideXlab platform.
-
Novel "After Minoxidil" spray improves topical Minoxidil compliance and hair style manageability.
Journal of cosmetic dermatology, 2020Co-Authors: Maja Kovacevic, John Mccoy, Jerry Shapiro, Rodney Sinclair, Sergio Vano-galvan, Mohamad Goldust, Mirna Šitum, Andy GorenAbstract:BACKGROUND Topical Minoxidil is the only US FDA-approved drug for the treatment of female pattern hair loss (FPHL). While the safety profile of topical Minoxidil is excellent, the efficacy of Minoxidil in hair growth is extremely low. A recent survey of 8000 people observed that only 4% of hair loss patients using an over-the-counter Minoxidil were very satisfied with their results. In contrast, in clinical studies with an intervening physician, approximately 30%-40% of patients demonstrate an appreciable benefit. Compliance with topical drug regimens is often a major obstacle, limiting their effectiveness. Topical Minoxidil leaves a greasy residue on the hair, which is especially problematic for women who do not wash their hair daily. AIMS We set out to develop an "After Minoxidil" companion spray to Minoxidil that removes residual Minoxidil from the hair, where it is not needed, yet leaves Minoxidil on the scalp where it is required. We hypothesized that improving the cosmetic properties of Minoxidil would improve patient compliance with the drug and subsequently improve clinical outcomes. METHODS A cohort of 20 FPHL patients was recruited to use the novel "After Minoxidil" spray and report changes in hair quality on a Likert scale. RESULTS In our cohort of FPHL patients, the novel "After Minoxidil" spray restored ease of styling and reduced greasiness to preMinoxidil level in 65% and 85% of subjects, respectively. The average reduction in perceived greasiness was 78%. Importantly, 70% of subjects interviewed stated they would likely continue to use the Minoxidil and "After Minoxidil" treatment regimen for 6 months, vs 0% willing to use Minoxidil alone. CONCLUSION The novel "After Minoxidil" spray improved ease of hair styling and reduced greasiness following application of topical Minoxidil; thus, the novel "After Minoxidil" spray may help improve drug compliance and efficacy.
-
the effect of topical Minoxidil treatment on follicular sulfotransferase enzymatic activity
Journal of Biological Regulators and Homeostatic Agents, 2018Co-Authors: Andy Goren, Maja Kovacevic, John Mccoy, Mirna Šitum, Rachita Dhurat, J Chitalia, T Naccarato, Torello LottiAbstract:Minoxidil is the only US FDA-approved topical drug for the treatment of female and male pattern hair loss. Previously, it was demonstrated that topical Minoxidil is metabolized to its active metabolite, Minoxidil sulfate, by sulfotransferase enzymes located in the outer root sheath of hair follicles. The expression of sulfotransferase in the scalp varies greatly between individuals, and this difference in expression explains the varied response to Minoxidil treatment. Previously, we have demonstrated the clinical utility of detecting sulfotransferase in plucked hair follicles to predict Minoxidil response in pattern hair loss patients. Typically, exogenous exposure to substrates affects the expression of the enzymatic system responsible for their metabolism. For example, Phase I metabolizing enzymes, such as the cytochrome P450 family of enzymes, are known to be up-regulated in the presence of xenobiotic substrates. However, it is not known if Phase II metabolizing enzymes, such as the sulfotransferase family of enzymes, are similarly affected by the presence of substrates. In this study, we recruited 120 subjects and analyzed their sulfotransferase enzymatic activity before and after treatment with topical Minoxidil. Adjusting the results for biologic (within subject) variability, we discovered that the sulfotransferase enzymatic system expression is stable over the course of Minoxidil treatment. To the best of our knowledge, this is the first study to demonstrate the stability of sulfotransferase, a Phase II metabolizing enzyme, over the course of Minoxidil treatment.
-
Minoxidil dose response study in female pattern hair loss patients determined to be non-responders to 5% topical Minoxidil.
Journal of biological regulators and homeostatic agents, 2016Co-Authors: John Mccoy, Maja Kovacevic, Andy Goren, Jerry ShapiroAbstract:Topical Minoxidil is the only US FDA approved drug for the treatment of female pattern hair loss (FPHL). 5% Minoxidil foam is only effective at re-growing hair in a minority of women (approximately 40%). Thus, the majority of FPHL patients remain untreated. Previously, we demonstrated that nonresponders to 5% Minoxidil have low metabolism of Minoxidil in hair follicles. As such, we hypothesized that increasing the dosage of topical Minoxidil to low metabolizers would increase the number of responders without increasing the incidence of adverse events. In this study, we recruited FPHL subjects that were identified as non-responders to 5% topical Minoxidil utilizing the previously validated assay for Minoxidil response. Subjects were treated for 12 weeks with a novel 15% topical Minoxidil solution. At 12 weeks, 60% of subjects achieved a clinically significant response based on target area hair counts (>13.7% from baseline), as well as significant improvement in global photographic assessment. None of the subjects experienced significant hemodynamic changes or any other adverse events. To the best of our knowledge, this is the first study to demonstrate the potentially beneficial effect of a higher dosage of Minoxidil in FPHL subjects who fail to respond to 5% Minoxidil.
-
doppler laser imaging predicts response to topical Minoxidil in the treatment of female pattern hair loss
Journal of Biological Regulators and Homeostatic Agents, 2016Co-Authors: John Mccoy, Maja Kovacevic, Mirna Šitum, Andrija Stanimirovic, Zeljana Bolanca, Andy GorenAbstract:Topical Minoxidil is the only drug approved by the US FDA for the treatment of female pattern hair loss. Unfortunately, following 16 weeks of daily application, less than 40% of patients regrow hair. Several studies have demonstrated that sulfotransferase enzyme activity in plucked hair follicles predicts topical Minoxidil response in female pattern hair loss patients. However, due to patients discomfort with the procedure, and the time required to perform the enzymatic assay it would be ideal to develop a rapid, non-invasive test for sulfotransferase enzyme activity. Minoxidil is a pro-drug converted to its active form, Minoxidil sulfate, by sulfotransferase enzymes in the outer root sheath of hair. Minoxidil sulfate is the active form required for both the promotion of hair regrowth and the vasodilatory effects of Minoxidil. We thus hypothesized that laser Doppler velocimetry measurement of scalp blood perfusion subsequent to the application of topical Minoxidil would correlate with sulfotransferase enzyme activity in plucked hair follicles. In this study, plucked hair follicles from female pattern hair loss patients were analyzed for sulfotransferase enzyme activity. Additionally, laser Doppler velocimetry was used to measure the change in scalp perfusion at 15, 30, 45, and 60 minutes, after the application of Minoxidil. In agreement with our hypothesis, we discovered a correlation (r=1.0) between the change in scalp perfusion within 60 minutes after topical Minoxidil application and sulfotransferase enzyme activity in plucked hairs. To our knowledge, this is the first study demonstrating the feasibility of using laser Doppler imaging as a rapid, non-invasive diagnostic test to predict topical Minoxidil response in the treatment of female pattern hair loss.
-
clinical utility and validity of Minoxidil response testing in androgenetic alopecia
Dermatologic Therapy, 2015Co-Authors: Andy Goren, John Mccoy, Jerry Shapiro, J L Roberts, Nisha Desai, Zoulikha Zarrab, Aldona Pietrzak, Torello LottiAbstract:Clinical response to 5% topical Minoxidil for the treatment of androgenetic alopecia (AGA) is typically observed after 3-6 months. Approximately 40% of patients will regrow hair. Given the prolonged treatment time required to elicit a response, a diagnostic test for ruling out nonresponders would have significant clinical utility. Two studies have previously reported that sulfotransferase enzyme activity in plucked hair follicles predicts a patient's response to topical Minoxidil therapy. The aim of this study was to assess the clinical utility and validity of Minoxidil response testing. In this communication, the present authors conducted an analysis of completed and ongoing studies of Minoxidil response testing. The analysis confirmed the clinical utility of a sulfotransferase enzyme test in successfully ruling out 95.9% of nonresponders to topical Minoxidil for the treatment of AGA.
Antonella Tosti - One of the best experts on this subject based on the ideXlab platform.
-
oral Minoxidil treatment for hair loss a review of efficacy and safety
Journal of The American Academy of Dermatology, 2020Co-Authors: Michael Randolph, Antonella TostiAbstract:Abstract Background Although topical Minoxidil is an effective treatment option for hair loss, many patients are poorly compliant due to the necessity to apply the medication twice a day, undesirable hair texture, and scalp irritation. Objective In recent years, oral Minoxidil at low dose has been proposed as a safe alternative. This study reviewed articles in which oral Minoxidil was utilized to treat hair loss to determine its efficacy and safety as an alternative to topical Minoxidil. Methods PubMed searches were performed to identify articles discussing oral Minoxidil as the primary form of treatment for hair loss published up to April 2020. Results A total of 16 studies with 622 patients were found discussing the use of oral Minoxidil as the primary treatment modality for hair loss. Androgenetic alopecia was the most studied condition, but other conditions included: telogen effluvium, lichen planopilaris, loose anagen hair syndrome, monilethrix, alopecia areata, and permanent chemotherapy induced alopecia. Limitations Larger randomized studies comparing the efficacy/safety of different doses with standardized objective measurements will be needed to clarify the best treatment protocol. Conclusion Oral Minoxidil was found to be an effective and well-tolerated treatment alternative for healthy patients having difficulty with topical formulations.
-
diffuse hypertrichosis during treatment with 5 topical Minoxidil
British Journal of Dermatology, 1997Co-Authors: A M Peluso, Cosimo Misciali, Colombina Vincenzi, Antonella TostiAbstract:Five women affected by androgenetic alopecia developed severe hypertrichosis of the face and limbs after 2-3 months of treatment with 5% topical Minoxidil. Minoxidil was discontinued and in all patients the hypertrichosis disappeared from the face and arms after 1-3 months, and from legs after 4-5 months. Systemic absorption of Minoxidil, and a high sensitivity to Minoxidil of the follicular apparatus in these areas, is hypothesized.